Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Apogee Therapeutics, Inc.NASDAQ: APGE
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt remains negative
Q2 FY2026 net debt was -$98.74M, compared with -$113.35M a year earlier.
Context
- Net debt amounted to 7.4% of total assets at the end of Q2 FY2026, down 9.8 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +12.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (122.7M) USD
- Year-over-year change
- +5.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (122.7M) | +5.6% |
| FY2024 | 2024-12-31 | (129.96M) | -11.8% |
| FY2023 | 2023-12-31 | (116.28M) | +23.4% |
| FY2022 | 2022-12-31 | (151.89M) | — |
Net Debt vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +12.9% is the 7th highest of 10, against a peer median of +34.7%.
- Net debt amounts to 7.4% of total assets for APGE, versus a peer median of 12.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.03B USD | +1254.5% | — | 79.1% | |
| Jun 2026 | $572.34M USD | +978.6% | +40.6% | 69.1% | |
| Sep 2026 | -$19.01M USD | +49.8% | — | 1.8% | |
IRONDisc Medicine, Inc. | Sep 2026 | -$28.9M USD | +73.7% | — | 4.1% |
| Mar 2026 | -$55.06M USD | -528.8% | — | 8.6% | |
| Sep 2026 | -$76.55M USD | +20.4% | — | 6.4% | |
| Jun 2026 | -$98.74M USD | +12.9% | — | 7.4% | |
| Sep 2026 | -$293.3M USD | -323.3% | — | 17.4% | |
| Jun 2026 | -$352.95M USD | +34.7% | — | 32.8% | |
AAPGAscentage Pharma Group International | Dec 2025 | -CN¥490.68M CNY | -213.6% | — | 12.4% |
| Peer median (excluding APGE) | — | +34.7% | +40.6% | 12.4% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.